Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5855226 | 0.88 | ESR1 (0.47) | ESR1ESR2HTR2BSIGMAR1 | |
| SCHEMBL5855951 | 0.86 | CYP19A1 (0.33) | HTR1AHTR2BSIGMAR1 | |
| SCHEMBL5857190 | 0.86 | ESR1 (0.45) | ESR1ESR2 | |
| SCHEMBL7588543 | 0.84 | PTPN1 (0.31) | — | |
| SCHEMBL7587357 | 0.84 | PTPN1 (0.31) | — | |
| SCHEMBL5856958 | 0.82 | BACE1 (0.34) | HTR1AHTR2BSIGMAR1 | |
| SCHEMBL5857401 | 0.81 | HTR2B (0.33) | HTR1AHTR2BSIGMAR1 | |
| SCHEMBL7588656 | 0.80 | ESR1 (0.36) | ESR1ESR2HTR2BSIGMAR1 | |
| SCHEMBL7585889 | 0.80 | ESR1 (0.36) | ESR1ESR2HTR2BSIGMAR1 | |
| SCHEMBL5857302 | 0.78 | ESR1 (0.31) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074819-B2 | Benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2004-05-27 | — | — | US | disclosed |
| US-6645951-B1 | Antiestrogens for treating breast cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | NR5A1, SHBG, ESR2 | ESR1 12/4885ESR2 3/4885HTR1A 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.